<DOC>
	<DOCNO>NCT01349816</DOCNO>
	<brief_summary>The primary objective study demonstrate efficacy PT003 MDI relative individual component ( PT001 MDI PT005 MDI ) patient moderate severe chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>PT003 MDI Dose Confirmation Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Key Signed write informed consent 40 80 year age Clinical history COPD airflow limitation fully reversible Females nonchild bear potential female child bear potential negative pregnancy test ; acceptable contraceptive method Current/former smoker least 10 packyear history cigarette smoke A measure post bronchodilator FEV1/FVC ratio &lt; = 0.70 A measure post bronchodilator FEV1 &gt; = 750ml 30 % predict &lt; = 80 % predict normal value Able change COPD treatment require protocol Key Women pregnant lactate Primary diagnosis asthma Alpha1 antitrypsin deficiency cause COPD Active pulmonary disease Prior lung volume reduction surgery Abnormal chest Xray ( CT scan ) due presence COPD Hospitalized due poorly control COPD within 3 month Screening Clinically significant medical condition preclude participation study ( e.g . clinically significant abnormal ECG , uncontrolled hypertension , glaucoma , symptomatic prostatic hypertrophy ) Cancer complete remission least 5 year Treatment investigational study drug participation another clinical trial study within last 30 day 5 half live Other inclusion/exclusion criterion define protocol</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>COPD</keyword>
</DOC>